Table 2.
Effect of methylglyoxal‐modified BSA (MG‐AGE) on cell shortening and relengthening properties in cardiomyocytes from control and STZ‐induced diabetic mice (2 hrs of treatment)
| Control | Methylglyoxal‐modified BSA (MG‐AGE) | ||||
|---|---|---|---|---|---|
| 0.1 μmol/l | 0.5 μmol/l | 2.5 μmol/l | 5.0 μmol/l | ||
| Control | |||||
| CL (μm) | 105.6 ± 3.6 | 102.6 ± 3.1 | 103.9 ± 2.7 | 101.9 ± 2.7 | 101.2 ± 2.8 |
| PS (% CL) | 5.39 ± 0.48 | 5.15 ± 0.47 | 5.37 ± 0.34 | 4.73 ± 0.33* | 4.10 ± 0.22* |
| +dL/dt (μm/sec.) | 134.3 ± 10.1 | 136.3 ± 10.7 | 132.3 ± 10.2 | 139.3 ± 8.5 | 116.5 ± 5.7* |
| –dL/dt (μm/sec.) | −144.7 ± 11.7 | −139.9 ± 11.4 | −140.0 ± 7.8 | −135.9 ± 7.9 | −112.2 ± 4.9* |
| TPS (ms) | 81 ± 4 | 77 ± 3 | 82 ± 3 | 96 ± 5* | 93 ± 7* |
| TR90 (ms) | 118 ± 6 | 124 ± 4 | 120 ± 5 | 183 ± 10* | 176 ± 12* |
| Diabetic | |||||
| CL (μm) | 96.5 ± 2.5# | 93.0 ± 2.5 | 92.7 ± 2.8 | 93.4 ± 3.0 | 91.8 ± 2.6 |
| PS (% CL) | 4.50 ± 0.45# | 4.72 ± 0.38 | 4.61 ± 0.23 | 4.56 ± 0.27 | 4.73 ± 0.28 |
| +dL/dt (μm/sec.) | 113.8 ± 9.3# | 108.6 ± 8.4 | 114.9 ± 5.6 | 110.6 ± 6.6 | 100.2 ± 7.8 |
| −dL/dt (μm/sec.) | −109.9 ± 9.8# | −103.0 ± 8.0 | −104.2 ± 8.1 | −76.4 ± 2.9* | −76.8 ± 6.4* |
| TPS (ms) | 95 ± 5# | 96 ± 5 | 105 ± 6 | 131 ± 8* | 130 ± 7* |
| TR90 (ms) | 141 ± 8# | 209 ± 12* | 241 ± 16* | 254 ± 13* | 250 ± 14* |
CL = cell length; PS = peak shortening; +dL/dt = maximal velocity of shortening;–dL/dt = maximal velocity of relengthening; TPS = time–to‐PS; TR90= time‐to 90% relengthening. Mean ± S.E.M., n= 50 cells per group, *P < 0.05 versus respective control (2.5 μmol/l BSA), #P < 0.05 versus control mice.